Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

Giorgio Frega\textsuperscript{a,b}, Qi Wu\textsuperscript{a,b}, Julie Le Naour\textsuperscript{c,d}, Erika Vacchelli\textsuperscript{e,f,g,h}, Lorenzo Galluzzi\textsuperscript{a,b,j,k}, and Oliver Kepp\textsuperscript{a,b}

\textsuperscript{a}Equipe labellisée par la Ligue Contre le Cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France; \textsuperscript{b}Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France; \textsuperscript{c}Department of Experimental, Diagnostic and Speciality Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; \textsuperscript{d}Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; \textsuperscript{e}Sandra and Meyer Meyer Cancer Center, New York, NY, USA; \textsuperscript{f}Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; \textsuperscript{g}Department of Dermatology, Yale School of Medicine, New Haven, CT, USA; \textsuperscript{h}Université de Paris, Paris, France; Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; \textsuperscript{i}Karolinska Institutet, Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, Sweden

ABSTRACT

Resiquimod (R848) and motolimod (VTX-2337) are second-generation experimental derivatives of imiquimod, an imidazoquinoline with immunostimulatory properties originally approved by the US Food and Drug Administration for the topical treatment of actinic keratosis and genital warts more than 20 years ago. Both resiquimod and motolimod operate as agonists of Toll-like receptor 7 (TLR7) and/or TLR8, in thus far delivering adjuvant-like signals to antigen-presenting cells (APCs). In line with such an activity, these compounds are currently investigated as immunostimulatory agents for the treatment of various malignancies, especially in combination with peptide-based, dendritic cell-based, cancer cell lysate-based, or DNA-based vaccines. Here, we summarise preclinical and clinical evidence recently collected to support the development of resiquimod and motolimod and other TLR7/TLR8 agonists as anticancer agents.

Introduction

Immunotherapy with immune checkpoint blockers (ICBs) such as ipilimumab, which targets cytotoxic T lymphocyte-associated protein 4 (CTLA4), as well as nivolumab and pembrolizumab, both of which target programmed cell death 1 (PD1D1, best known as PD-1), has literally revolutionized the clinical management of a variety of tumors, including (but not limited to) melanoma, nonsmall cell lung carcinoma (NSCLC) and urothelial carcinoma, and it holds promise to benefit an even higher amount of patients, either alone or in the context of combinatorial regimes, over the next few years.\textsuperscript{1-8} Nonetheless, attention on alternative immunotherapeutic approaches has remained high, at least in part reflecting: (1) the relatively small fraction of patients responding to ICBs employed as single agents;\textsuperscript{9-11} (2) the considerable side effects associated with some ICBs, especially when combined with each other;\textsuperscript{12-15} and (3) the economic burden of ICB-based immunotherapy.\textsuperscript{5,6} Besides monoclonal antibodies that operate as agonists of co-stimulatory receptors on immune effector cells,\textsuperscript{18-20} such immunotherapeutic agents include small molecules that trigger Toll-like receptor (TLR) signaling,\textsuperscript{21-29} de facto providing antigen-presenting cells (APCs) such as dendritic cells (DCs)\textsuperscript{30-32} with adjuvant-like, maturation signals that support the initiation of anticancer immunity (rather than tolerance).\textsuperscript{22,33-38}

TLRs are evolutionary conserved pattern recognition receptors (PRRs) localized at the cell surface or in endosomal compartments, and act as key mediators of innate immunity.\textsuperscript{26,39-43} As a family, TLRs play a crucial role in ensuring a first line of defense against pathogens, largely based on their ability to respond to conserved microbial structures commonly referred to as microbe-associated molecular patterns (MAMPs) by initiating the secretion of bioactive factors including numerous cytokines.\textsuperscript{40,44-47} Alongside this pristine antimicrobial function, TLRs also respond to a number of endogenous cues commonly referred to damage-associated molecular patterns (DAMPs), which are critical for the detection of cell stress and death as immunogenic in sterile conditions.\textsuperscript{48-52} As of today, no less than 13 TLRs have been identified in mammals (10 in humans),\textsuperscript{43,53} each of which exhibits (at least some) degree of specificity for selected MAMPs or DAMPs.\textsuperscript{43,53,54} Thus, while bacterial lipopolysaccharide generally operates as a mixed TLR2/TLR4 agonist,\textsuperscript{55-58} CpG-rich oligodeoxynucleotides initiate immune signaling upon binding to TLR9.\textsuperscript{59-61} However, while surface-exposed TLRs (i.e., TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10) as a group recognize a panel of chemical entities, including (but not limited to) proteins, lipoproteins, and lipopolysaccharides, endosomal TLRs (i.e., TLR3, TLR7, TLR8, TLR9), generally respond to (both microbial and endogenous) nucleic acids.\textsuperscript{21,24,62} In this setting, TLR signaling is largely governed by ligand (1) availability, (2) localization, and (3) structure.\textsuperscript{63,62} On activation, all TLRs but TLR3 signal via a molecular mechanism involving MYD88 innate immune signal transduction adaptor (MYD88), which culminates in the NF-kB-dependent or interferon regulatory factor 3 (IRF3)-dependent secretion of pro-inflammatory
cytokines. Conversely, TLR3 obligatorily drives cytokine synthesis via Toll-like receptor adaptor molecule 1 (TICAM1, best known as TRIF). Over the past two decades, the potent immunostimulatory effects of TLRs have spurred efforts aimed at the development of TLR agonists as anticancer agents, especially (but not exclusively) for use as immunological adjuvants to DC-based, peptide-based, or DNA-based therapeutic vaccines. TLR7 and TLR8, which respond to single-stranded RNA rich in uridine and guanosine have been considered as promising targets in this sense, at least in part reflecting the notion that the TLR7 agonist imiquimod has been approved for use as topical standalone agents in patient with actinic keratosis and genital warts as early as in 1997. In this context, two imidazolizine derivatives of imiquimod, namely resiquimod (a mixed TLR7/8 agonist also known as R848) and motolimod (a TLR8 agonist also known as VTX-2337) have been shown to mediate promising immunostimulatory activity in a variety of preclinical models, including models of anticancer immunotherapy. However, neither of these agents has yet been approved by regulatory agencies for use in cancer patients. Along similar lines, a few third-generation TLR7/TLR8 agonists has entered clinical development for the treatment of viral infection or cancer based on promising preclinical results, including PF-4878691, BDC-1001, LHC165, NKTR-262, TQ-A3334, RO7119929, DSP-0509, BNT411, and NJH395. However, none of these molecules has obtained regulatory approval for use in humans so far.

Here, we summarize recent preclinical and clinical data on the ability of these TLR7 and/or TLR8 agonists to (re)instate anticancer immunosurveillance, as we delineate the current portfolio of clinical trials testing resiquimod and motolimod in patients with cancer.

Recent preclinical developments

Since the publication of the latest Trial Watch dealing with experimental TLR7/TLR8 agonists for cancer therapy (October 2018), a number of preclinical studies on this topic have been published or presented at major international conferences on cancer (immune)therapy. We found the following selected reports of particular interest.

Masud Alam and collaborators (National Cancer Institute, Frederick, MD, USA) showed that the TH1-polarizing alarm high mobility group nucleosome binding domain 1 (HMGN1) and resiquimod synergize at driving the functional maturation of human monocyte-derived DCs (MoDCs) and mouse bone marrow-derived DCs (BMDCs), which is accompanied by NF-κB activation, upregulation of DC surface proteins including CD80, CD83, CD86, and HLA-DR, and production of pro-inflammatory cytokines such as interleukin (IL)-12, IL-18, and tumor necrosis factor (TNF). Moreover, HMGN1 and resiquimod were found to synergize at triggering the nuclear translocation of interferon regulatory factor 3 (IRF3) and IRF7, and hence at driving the secretion of type I IFN from DCs. Consistently, transcriptomic studies of human MoDCs revealed that the combination of HMGN1 and resiquimod synergistically upregulate the expression of genes involved in DC maturation and the polarization of immune responses toward a TH1 profile. Ryan et al. (Washington State University, Pullman, WA, USA) developed an enzyme-directed immunostimulant (EDI) produg of resiquimod, which can be metabolized to the active drug by cancer cells and ultimately released into the tumor microenvironment to mediate immunostimulatory effects. This agent exhibited immunostimulatory activity in a panel of transplantable mouse models of melanoma (B16 cells), prostate carcinoma (TC2 cells), and breast carcinoma (4T1 cells). Lu and colleagues (University of Kansas, Lawrence, KS, USA) tested yet another produg-based nanocarrier delivery system for resiquimod. Specifically, resiquimod was linked with α-tocopherol to generate a produg that was further modified with hyaluronic acid into a polymeric nano-suspension (HA-Toco). In vitro studies demonstrated that this delivery system prolongs the kinetics of resiquimod release while maintaining its immunostimulatory activity. When administered subcutaneously to rabbits, the nano-suspension formed a depot at the injection site, inducing localized immune responses without systemic expansion. This formulation also suppressed the growth of oral squamous cell carcinoma (OSCC) AT84 cells growing in immunocompetent syngeneic C3 H mice, correlating with the recruitment of CD8A+ and CD11b+ immune cells to the tumor bed. Finally, HA-Toco induced a 67% response rate (three partial remissions and one complete remission) in dogs spontaneously developing mast cell tumors. Lu and coauthors (Tianjin University, Tianjin, China) designed nanoparticles (NPs) based on polydopamine (PDA) loaded with resiquimod and a fluorescent agent that can be released by photothermal therapy, which they dubbed PDA-PEG-R848-CD NPs. Upon exposure to photothermal therapy, this nanomedicine not only was able to eradicate mouse 4T1 mammary tumors established in immunocompetent BALB/c mice but also prevented metastatic dissemination to the lungs and liver and mediated abscopal effects on distant, nonirradiated lesions, suggesting a potential for combination with ICIs. Liu and collaborators (Southern Medical University, Guangzhou, China) found that resiquimod reversed the inhibitory effect of oxaliplatin, an immunogenic chemotherapeutic agents commonly employed for the therapy of colorectal carcinoma, on the differentiation of myeloid-derived suppressor cells (MDSCs) into M1-like macrophages, and enhanced its cytotoxic effect on malignant cells to limit the growth of mouse colorectal carcinoma CT26 cells in vivo. Along similar lines, Rodel et al. (Harvard Medical School, Boston, MA, USA) identified resiquimod as a potent driver of M1 macrophage polarization in a morphometry-based screen for drugs capable to reeducate macrophages, and showed that resiquimod-loaded β-cycloexetrin nanoparticles (CDNPs-R848) efficiently deliver resiquimod to tumor-associated macrophages (TAMs) in C57BL/6 mice bearing MC38 colorectal tumors. Moreover, CDNPs-R848 altered the functional orientation of TAMs toward an M1 phenotype in vivo, culminating only with a decrease in tumor growth but also with the establishment of long-term immunological memory. Taken together, these results suggest that chemoresistance to oxaliplatin might arise from the suppression of M1 differentiation in the tumor microenvironment, and that resiquimod constitutes a promising immunological adjuvant for oxaliplatin-based chemotherapy.
Michaelis and colleagues (Oregon Health & Science University, Portland, OR, USA) showed that resiquimod induces antitumor responses and attenuates cachexia in syngeneic orthotopic murine models of pancreatic ductal adeno-carcinoma (PDAC).92 This study revealed that resiquimod acts on both the host and the tumor to enable disease control. In particular, behavioral and molecular phenotyping on tumor-bearing mice delineated a resiquimod-mediated decrease in manifestations of cachexia,92 resulting in a nearly doubled overall survival for tumor-bearing mice.92 Moreover, tumors arising from two out of three PDAC cell lines responded to resiquimod with a decrease in growth and an increase in immune complexity, an increase in CD8+ T-cell infiltration and a decrease in the intratumoral frequency of CD4+CD25+FOXP3+ regulatory T (TREG) cells.92 Finally, stromal (not neoplastic) TLR7 was a prerequisite for resiquimod responses, which is in line with TLR7 expression by stromal but not epithelial tissue from patient samples.92 These data point to the possibility that resiquimod may be useful for the treatment of cachexia in patients with PDAC.

Mullins and collaborators (AstraZeneca Ltd, Cambridge, UK) harnessed quantitative methods including mass spectrometry imaging to demonstrate that the lipophilic TLR7/8 agonist MEDI9197 (also known as 3 M-052) is retained at the injection site in mouse bearing syngeneic B16-OVA melanoma cells, resulting in limited systemic exposure.92 MEDI9197 injection led to a T1/1 polarized immune response accompanied by activation of natural killer (NK) and CD8+ T cells,96 secretion of a broad range of cytokines including type I IFN, IL-12 and interferon gamma (IFNG) and inhibition of tumor growth.92 These beneficial effects could be further boosted by the co-administration of immunostimulatory antibodies specific for TNF receptor superfamily member 4 (TNFRSF4, best known as OX40) and TNFRSF18 (best known as GITR).92

Yosuke et al. (Sumitomo Dainippon Pharma Co., Ltd, Osaka, Japan) showed that DSP-0509 delivered i.v. efficiently controls the growth of mouse tumors with high mutational burden, robust CD8+ T cell infiltration and a globally inflamed microenvironment, such as colorectal carcinoma CT26 cells, but not tumors with low mutational rates, limited T-cell recruitment, and a globally suppressive microenvironment, such as mammary carcinoma 4T1 cells.97 Conversely, the combination of DSP-0509 with ICs targeting CTLA4 or PD-1 was effective in both models, consistent with an increased expression of genes linked to immune effector functions like IFNG, and a decreased in immunosuppressive cell populations including neutrophils and polymorphonuclear MDSCs.97 This study suggest that DSP-0509 can be employed to convert immunologically “cold,” ICB-resistant tumors into immunologically “hot” lesions that respond to ICs.

Finally, Ackerman et al. (Bolt Biotherapeutics, Redwood City, CA, USA) developed an immune-stimulating antibody conjugate (ISAC) composed of a TLR7/8 agonist conjugated to a tumor-targeting monoclonal antibody.98 Cocultures of human leukocytes and cancer cell lines demonstrated that this ISAC can activate APCs, resulting in upregulation of costimulatory molecules, secretion of proinflammatory cytokines, as well as effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).98 Moreover, in syngeneic tumor models, ISAC administration mediated robust therapeutic effects coupled to the establishment of immunological memory.

Altogether, these studies suggest that considerable efforts are currently being dedicated to the development of delivery platform for TLR7/TLR8 agonists that enable robust local activity in the absence of systemic exposure.

**Completed clinical trials**

Since the publication of the latest Trial Watch dealing with TLR7/TLR8 agonists (October 2018),92 the results of only two clinical studies testing these agents for the treatment of cancer patients have been published in the peer-reviewed literature.

Topical resiquimod has been tested as a standalone therapeutic intervention in 217 patients with actinic keratosis, a common precancerous lesion of the skin that is linked to excessive sun exposure.78,99,100 with the purpose of determining optimal dose with respect to efficacy, safety and tolerability (NCT01583816).92 Patients were randomized to daily 0.01% or 0.03% resiquimod cream in five different treatment schedules until skin erosion or up to 8 weeks. Complete clinical clearance was obtained in up 56% to 85% of patients, depending on study group, with maximal efficacy being observed among individual receiving the 0.03% formulation.92 One hundred and eighteen patients experience treatment-related adverse effects (TRAEs), the majority of which was mild.92

Motolimod has been tested as an adjuvant to cytotoxic chemotherapy in a Phase 2 clinical trial enrolling 195 adults with histologically confirmed recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) (NCT01836029).101,102 In this setting, motolimod was well tolerated but failed to improve the therapeutic activity of the so-called “EXTREME” regimen,102 consisting of a platinum derivative (generally carboplatin or cisplatin),103-107 fluorouracil and cetuximab.108-110 However, patients with human papillomavirus (HPV)+ tumors as well as individuals experiencing injection site reactions upon motolimod administration experience improved disease outcome in response to the combinatorial regimen,102 suggesting that this approach could at least benefit specific subsets of HNSCC patients.

The limited number of original reports on clinical studies investigating TLR7 and TLR8 agonists for cancer therapy points to a somehow decreased interest in this therapeutic paradigm, potentially linked to the emergence of other promising immunotherapeutic agents including ICBs,2,4 oncolytic viruses,111,112 and CAR T cells.113,114

**Ongoing clinical trials**

Since the submission of the latest Trial Watch dealing with this topic (October 2018),25 only 10 clinical studies involving the administration of TLR7 (6 studies), TLR8 (2 studies), or mixed TLR7/TLR8 (2 studies) agonists to cancer patients have been initiated (Table 1) (source <https://www.clinicaltrials.gov>).

At least 6 different TLR7 agonists other than resiquimod have recently entered clinical development. Thus, the tolerability, safety, pharmacodynamics, pharmacokinetics, and preliminary
Table 1. Clinical trials testing experimental TLR7 and TLR8 agonists in cancer patients*.

| Target(s) | Agonist | Indication(s) | Phase(s) | Status | Route | Notes | Ref. |
|-----------|---------|---------------|----------|--------|-------|-------|------|
| TLR7      | 852A    | ALL AML CLL Lymphoma Multiple myeloma | II       | Terminated | s.c. | As single agent | NCT0076159 |
|           |         | Breast cancer Cervical cancer Endometrial cancer Ovarian cancer | II       | Completed | s.c. | As single agent | NCT0319748 |
| Breast    |         | Melanoma      | II       | Completed | i.v. | As single agent | NCT0018932 |
|           |         | Melanoma      | I        | Completed | Topical | As single agent | NCT00891689 |
| Chemorefractory solid tumors | I | Completed | i.v. | As single agent | NCT0095160 |
| BNT411    | ES-SCLC Solid tumors | I/II | Not yet recruiting | i.v. | As single agent or combined with atezolizumab and chemotherapy | NCT04101357 |
| DSP-0509  | Advanced solid tumors | I/II | Recruiting | i.v. | As single agent or combined with pembrolizumab | NCT03416335 |
| LHC165    | Advanced solid tumors | I | Recruiting | i.t. | As single agent or combined with PDR001 | NCT03301896 |
| NHH395    | Advanced HER2+ solid tumors | I | Recruiting | i.v. | As single agent | NCT03696771 |
| Resiquimod | Actinic keratosis | II | Completed | Topical | As single agent | NCT01588381 |
| Brain tumors | CTCL | II | Active, not recruiting | Topical | Combined with DCs pulsed with autologous tumor cell lysates | NCT01204684 |
|           | Melanoma | I | Completed | Topical | As single agent | NCT01676831 |
|           | I/II | Completed | Topical | Combined with a peptide-based vaccine | NCT01748747 |
|           | I/III | Active, not recruiting | Topical | Combined with a peptide-based vaccine | NCT00470379 |
|           | II | Active, not recruiting | Topical | Combined with a peptide-based vaccine | NCT02126579 |
| MIBC      | II | Terminated | Topical | Combined with a peptide-based vaccine | NCT00960752 |
| nBCC      | II/III | Terminated | Topical | As single agent | NCT01094496 |
| NY-ESO-1+ tumors | | I/II | Completed | Topical | Combined with CDX-1401 ± poly-ICLC | NCT01808950 |
| Advanced tumors | | I/II | Completed | Topical | Combined with a peptide-based vaccine | NCT00821652 |
| RO7119929 | Biliary tract tumors HCC Hepatic metastases | Not yet recruiting | p.o. | As single agent or combined with anlotinib | NCT04338685 |
| TQ-A3334 | NSCLC | I/II | Recruiting | p.o. | As single agent or combined with anlotinib | NCT04273815 |
| TLR7 TLR8 | BDC-1001 | HER2+ advanced solid tumors | I | Recruiting | n.s. | As single agent or combined with pembrolizumab | NCT04278144 |
| CV8102    | ACC HNSCC Melanoma SCC | I/II | Recruiting | n.s. | As single agent or combined with standard of care PD-1 blockade | NCT03291002 |
|           | HCC | I/II | Completed | i.d. | Combined with cyclophosphamide and a peptide-based vaccine | NCT03203005 |
| NKTR-262  | Advanced/metastatic solid tumors | I/II | Recruiting | i.t. | Combined with pegylated IL2 ± nivolumab | NCT03435640 |
| TLR8      | Motolimod | Advanced solid tumors | I | Terminated | s.c. | Combined with cyclophosphamide and pegylated G-CSF | NCT02650635 |
|           | | I | Completed | s.c. | Combined with cetuximab | NCT01343177 |
| HNSCC     | I | Recruiting | i.t. s.c. | As single agent or combined with nivolumab | NCT03906526 |
|           | I | Terminated | s.c. | Combined with cetuximab ± nivolumab | NCT02124580 |
|           | I | Not yet recruiting | i.t. | Combined with nivolumab | NCT04272333 |
|           | | Completed | n.s. | Combined with cetuximab and multimodal chemotherapy | NCT01383609 |
| Lymphoma  | I | Terminated | i.t. | Combined with radiation therapy | NCT01289210 |
| Ovarian cancer | I | Completed | s.c. | Combined with paclitaxel or PLD | NCT01294293 |
|           | I/II | Active, not recruiting | s.c. | Combined with durvalumab and PLD | NCT02431559 |

Abbreviations: ACC, adenoid cystic carcinoma; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CTCL, cutaneous T-cell lymphoma; DC, dendritic cell; ES-SCLC, extensive-stage small cell lung cancer; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; i.d., intradermal; i.t., intra tumor; i.v., intravenous; MIBC, muscle-invasive bladder cancer; nBCC, nodular basal cell carcinoma; n.s., not specified; NSCLC, non-small cell lung carcinoma; PLD, pegylated liposomal doxorubicin; poly-ICLC, polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose; p.o., per os; s.c., subcutem; SCC, squamous cell carcinoma.* All clinical trials listed on http://clinicaltrials.gov/at the date of submission.
activity profile of RO7119929 administered as standalone therapeutic intervention are being evaluated in patients with unresectable advanced or metastatic hepatocellular carcinoma (HCC), biliary tract cancer, or other solid tumors with predominant liver involvement and metastases (NCT04338685). Similarly, the erb-b2 receptor tyrosine kinase 2 (ERBB2, best known as HER2)-targeted TLR7 agonist ISAC NJH395\textsuperscript{15,116} is being tested as monotherapy in patients with nonbreast HER2\textsuperscript{*} advanced solid neoplasms (NCT03696771). Along similar lines, the HER2-targeted TLR7/TLR8 mixed agonist ISAC BDC-1001 is being evaluated in a first-in-human trials enrolling individuals with HER2\textsuperscript{*} breast and gastric carcinoma (NCT04278144). This study is planned over four distinct phases aiming at identifying the maximum tolerated dose (MTD) of BDC-1001 as monotherapy (phase 1) or combined with the PD-1 blocker pembrolizumab (phase 2), and testing preliminary efficacy of BD-1001 as standalone intervention (phase 3) or in combination with pembrolizumab (phase 4).

The Phase I/IIa dose-escalation clinical trial NCT04101357 is assessing the efficacy, pharmacodynamics, pharmacokinetics and safety of BNT411, a novel TLR7 agonist, either given as a monotherapy in individuals affected by advanced solid tumors or administered in combination with the PD-L1-targeted ICB atezolizumab,\textsuperscript{3,17–19} carbotatin and etoposide\textsuperscript{120,121} in patients with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). The synthetic TLR7 agonist DSP-0509 is being investigated for pharmacokinetic profile, tolerability, and safety upon intravenous administration as monotherapy or combined with pembrolizumab,\textsuperscript{122–124} in adults with advanced solid malignancies (NCT03416335). Similar approaches under clinical testing involve the hitherto experimental PD-1-targeting agent spartalizumab (also known as PDR001)\textsuperscript{125–128} and the TLR7 agonistic benzonaphtyrindine LHC165,\textsuperscript{95} (NCT03301896), the PD-1-specific ICB nivolumab and the mixed TLR7/TLR8 agonist NKTR-262,\textsuperscript{129} (NCT03435640), as well as nivolumab and motolimod (NCT04272333, NCT03906526). NCT03301896 consists of four dose escalation-phases followed by two expansion phases and is expected to include approximately 206 patients with advanced or metastatic solid tumors. In the context of NCT03435640, patients suffering from advanced solid neoplasms are planned to receive NKTR-262 in combination with NKTR-214 (a genetically engineered version of IL-2 specifically targeted to interleukin 2 receptor subunit beta, IL2RB)\textsuperscript{130} ± nivolumab. NCT04272333 aims at exploring the therapeutic profile and immunogenicity of nivolumab plus motolimod delivered i.t. in microdoses\textsuperscript{131–134} to patients with HNSCC. Finally, the pharmacokinetics, tolerance, effectiveness, dose-limiting toxicity (DLT) and MTD of the highly selective TLR7 agonist TQ-A3334 are being assessed in the dose-escalation/expansion study NCT04273815. In this setting, patients with NSCLC will TQ-A3334 p.o. as monotherapy or in combination with the multitarget receptor tyrosine kinase inhibitor anlotinib.\textsuperscript{135–137}

The status of the following clinical trials discussed in our previous Trial Watches dealing with TLR7 and TLR8 agonists,\textsuperscript{22} has changed during the past 20 months: NCT00960752 which is now listed as “Active, not recruiting”; NCT00821652, NCT00948961, NCT01294293, NCT01334177, NCT01583816 and NCT01748747 which are listed as “Completed”; as well as NCT02124850, NCT02650635, NCT01094496, NCT01808950, and NCT01289210, which have been “Terminated”, due to sponsor request (NCT02650635), slow enrollment (NCT01094496 and NCT01289210) or safety issues (NCT01808950) (source https://www.clinicaltrials.gov/). To the best of our knowledge, the results of the aforementioned completed trials have not been released yet, with the exception of NCT01583816 and NCT01836029 (see above).

**Concluding remarks**

In conclusion, the development of resiquimod, motolimod and other TLR7/TLR8 agonists as immunostimulatory agents for use in cancer patients appears to stand at an impasse, at least in part reflecting the disappointing results obtained in recent clinical tests. It is tempting to speculate that the limited clinical success of therapeutic cancer vaccines adjuvanted with TLR7/TLR8 agonists may not (entirely) originate from suboptimal TLR stimulation, but rather reflect limitations that are intrinsic to DC-based, peptide-based, and DNA-based vaccines (Figure 1).\textsuperscript{138,139} The identification of therapeutic strategies that circumvent resistance mechanisms such as antigen or beta-2-microglobulin (B2 M) loss,\textsuperscript{140,141} the robust immunosuppressive circuitries that characterize most solid tumors,\textsuperscript{142–144} as well as the loss of key proteins that underlie cancer cell sensitivity to immune effectors, such as caspase 8 (CASP8) and Janus kinase 2 (JAK2),\textsuperscript{145,146} may therefore pave the way to novel approaches that will ultimately benefit from TLR7/TLR8 agonism. Additional work in this sense is urgently awaited.

![Figure 1](https://www.oncoimmunology.com/images/f1.png)
Abbreviations

ADCC  Antibody-dependent cell-mediated cytotoxicity
ADCP  Antibody-dependent cellular phagocytosis
AK    Actinidic keratosis
APC   Antigen presenting cell
DAMP  Damage-associated molecular pattern
DC    Dendritic cell
DLD  Dose-limiting toxicity
HNSCC Head and neck squamous cell carcinoma
HPV   Human papilloma virus
HSV   Herpes simplex virus
ICB   Immune checkpoint blockerc
IFN   Interferon
IL    Interleukin
ISAC  Immune stimulating antibody conjugate
MAMP  Microbe-associated molecular pattern
MTD   Maximum tolerated dose
PLD   Pegylated liposomal doxorubicin
PRR   Pattern recognition receptor
TLR   Toll-like receptor

Acknowledgments

LG is supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD), Breast Cancer Research Program (BRCP) (#BC180476P1), by the 2019 Laura Ziskin Prize in Translational Research (#ZP-6177, PI: Formenti) from the Stand Up to Cancer (SU2C), by a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukemia and Lymphoma Society (LLS), by a startup grant from the Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US), by a Rapid Response Grant from the Functional Genomics Initiative (New York, US), by industrial collaborations with Lytix (Osel, Norway) and Phospatin (New York, US), and by donations from Phospatin (New York, US), the Luke Heller TECPR2 Foundation (Boston, US) and Sotio a.s. (Prague, Czech Republic). GG is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Le Cancer du Sein, Parlons-en!”; Cancéropôle Ile-de-France; Chancellerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085), Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology (ANR-18-IDEX-0001); the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

ORCID

Julie Le Naour https://orcid.org/0000-0002-3749-2171
Erika Vaccelli https://orcid.org/0000-0001-8010-0594
Lorenzo Galluzzi https://orcid.org/0000-0003-2257-8500
Guido Kroemer https://orcid.org/0000-0002-9334-4405
Oliver Kepp https://orcid.org/0000-0002-6081-9558

References

1. Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez-Soto A. The hallmarks of successful antitumor immunotherapy. Sci Transl Med. 2018;10:eaa7807. doi:10.1126/scitranslmed.aat7807.
2. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61. doi:10.1126/science.aaa8172.
3. Vitale I, Sistigu A, Manic G, Rudqvist N-P, Trajanoski Z, Galluzzi L. Mutational and antigenic landscape in tumor progression and cancer immunotherapy. Trends Cell Biol. 2019;29:396–416. doi:10.1016/j.tcb.2019.01.003.
4. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–214. doi:10.1016/j.cell.2015.03.030.
5. Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020;17:137–150. doi:10.1038/s41575-020-0282-3.
6. Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020;20:75–76. doi:10.1038/s41577-020-0300-y.
7. Petroni G, Formenti SC, Chen-Kiang S, Galluzzi L. Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol. 2020. doi:10.1038/s41577-020-0275-8.
8. Rodriguez-Ruiz ME, Vitale I, Harrington KJ, Melero I, Galluzzi L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat Rev. 2020;21:120–134. doi:10.1038/s41579-019-0561-4.
9. Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20:25–39. doi:10.1038/s41577-019-0218-4.
10. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330. doi:10.1038/nature21349.
11. Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016;164:1233–1247. doi:10.1016/j.cell.2016.01.049.
12. June CH, Warshaw JT, Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med. 2017;23:540–547. doi:10.1038/nm.4321.
13. Esfahani K, Calabrese L. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020. doi:10.1038/s41578-020-0352-8.
14. Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashita MA, Lambotte O, Mariette X, Pratt A, Suárez-Almazor ME, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38. doi:10.1038/s41572-020-0160-6.
15. Herrmann J. Adverse cardiac effects of cancer therapies: cardio-toxicity and arrhythmia. Nat Rev Cardiol. 2020;17:474–502. doi:10.1038/s41569-020-0258-1.
16. Yu PP, Eton O, Garrison LP. Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. J Immunother Cancer. 2019;7:235. doi:10.1186/s41425-019-0079-9.
17. Chu JN, Choi J, Ostvar S, Torchia JA, Reynolds KL, Tramontano A, Gainor JF, Chung DC, Clark JW, Hur C, et al. Cost-effectiveness of immune checkpoint inhibitors for microrna stability-high/ mismatch repair-deficient metastatic colorectal cancer. Cancer. 2019;125:278–289. doi:10.1002/cncr.31795.
18. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95–106. doi:10.1038/nrc2051.
19. Levesque S, Le Naour J, Pietrocola F, Paillet J, Kremer M, Castoldi F, Baracco EE, Wang Y, Vacchelli E, Stoll G, et al. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. Oncoimmunology. 2019;9: e1657375. doi:10.1080/2162402X.2019.1657375.
20. Ahern E, Harjupää H, O’Donnell JS, Allen S, Dougall WC, Teng MVL, Smyth MJ. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade.
in mouse models of cancer. Oncoimmunology. 2018;7:e1431088. doi:10.1080/2162402X.2018.1431088.

21. Medler T, Patel JM, Alice A, Baird JR, Hu HM, Gough MJ. Activating the nucleic acid-sensing machinery for antiviral immunity. Int Rev Cell Mol Biol. 2019;344:173–214. doi:10.1016/bs.irbmb.2018.08.006.

22. Smith M, García-Martin E, Fitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: toll-like receptor agonists in cancer immunotherapy. Oncoimmunology. 2018;7:e152650. doi:10.1080/2162402X.2018.152650.

23. Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E, Melero I. An RNA toolbox for cancer immunotherapy. Nat Rev Drug Discov. 2018;17:751–767. doi:10.1038/s41573-019-00215-7.

24. Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20:95–112. doi:10.1038/s41577-019-0208-1.

25. Choi HW, Klessig DF. DAMPs, MAMPs, and sensing in plant innate immunity. BMC Plant Biol. 2016;16:232. doi:10.1186/s12870-016-0921-2.

26. Versluis M, Tarkowski LP, Van den Ende W. Fructans AS DAMPs or MAMPs: evolutionary prospects, cross-tolerance, and multistress resistance potential. Front Plant Sci. 2016;7:2061. doi:10.3389/fpls.2016.02061.

27. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev. 2015;13:405–414. doi:10.1038/nri3845.

28. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15:87–103. doi:10.1038/nri3787.

29. Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother. 2020;43:1–31. doi:10.1111/jitc.2019.00037.

30. Pouwels SD, Heijink IH, Ten Hacken NH, Vandenabeele P, Krysko DV, Nawijn MC, van Oosterhout AJ. DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol. 2014;7:215–226. doi:10.1038/mi.2013.77.

31. Garg AD, Galluzzi L, Apetah L, Baert T, Birge RB, Bravo-San Pedro JM, Brecqput K, Brough D, Chaurio R, Cironne M, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 2015;6:588. doi:10.3389/fimmu.2015.00588.

32. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860–875. doi:10.1038/nrc3380.

33. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111. doi:10.1038/nri.2016.107.

34. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461. doi:10.3389/fimmu.2014.00461.

35. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291–295. doi:10.1126/science.1183021.

36. Poltorak A, He X, Smirnova I, Liu MY, Van Hulfél C, Du X, Birdwell D, Aléjos E, Silva M, Galanos C, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;280:2085–2088. doi:10.1126/science.280.5396.2085.

37. Hirschfeld M, Ma Y, Weis JV, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol. 2000;165:618–622. doi:10.4049/jimmunol.165.2.618.

38. Lippitz BE, Harris RA. A translational concept of immuno-radiobiology. Radiother Oncol. 2019;140:116–124. doi:10.1016/j.radonc.2019.06.001.

39. Bryant CE, Spring DR, Gangloff M, Gay NJ. The molecular basis of the host response to lipopolysaccharide. Nat Rev Microbiol. 2010;8:8–14. doi:10.1038/nrmicro2266.

40. Haas T, Metzger J, Schmitz F, Heit A, Muller T, Latz E, Wagner H. The DNA sugar backbone 2’ deoxyribose determines toll-like receptor 9 activation. Immunity. 2008;28:315–323. doi:10.1016/j.immuni.2008.01.013.

41. Humbert M, Huges S. Warming up the tumor microenvironment in order to enhance immunogenicity. Oncoimmunology. 2019;8:1510710. doi:10.1080/2162402X.2018.1510710.

42. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5:471–484. doi:10.1038/nrd2059.
62. Roers A, Hiller B, Hornung V. Recognition of endogenous nucleic acids by the innate immune system. Immunity. 2016;44:739–754. doi:10.1016/j.immuni.2016.04.002.

63. Schlee M, Hartmann G. Discriminating self from non-self in nucleic acid sensing. Nat Rev Immunol. 2016;16:566–580. doi:10.1038/nri.2016.78.

64. Kawasaki T, Kawai T. Discrimination between self and non-self-nucleic acids by the innate immune system. Int Rev Cell Mol Biol. 2019;341:1–30. doi:10.1016/ircl.2018.08.004.

65. Palaudan SR, Reintert LS, Hornung V. DNA-stimulated cell death: implications for host defence, inflammatory diseases and cancer. Nat Rev Immunol. 2019;19:141–153. doi:10.1038/s41577-018-0117-0.

66. O’Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol. 2013;13:453–460. doi:10.1038/nri3446.

67. O’Neill LA, Bowie AG. The family of five: TLR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7:353–364. doi:10.1038/nri2079.

68. Farahnak S, Chronopoulos J, Martin GM. Nucleic acid sensing in allergic disorders. Int Rev Cell Mol Biol. 2019;345:1–33. doi:10.1016/ircl.2018.11.001.

69. Vecchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2013;2:e255771. doi:10.4161/onci.255771.

70. Kim YS, Park HJ, Park JH, Hong EJ, Jang G-Y, Jung ID, Han HD, Lee S-H, Vo M-C, Lee J-J, et al. A novel function of APIS (apoptosis inhibitor 5). TLR4-dependent activation of antigen presenting cells. Oncoimmunology. 2018;7:e1742187. doi:10.1080/2162402X.2018.1472187.

71. Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine. 2007;25(Suppl 2):S72–88. doi:10.1016/j.vaccine.2007.06.043.

72. Bezu L, Kepp O, Cerrato G, Pol J, Fučíková J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide-based vaccines in anticancer therapy. Oncoimmunology. 2018;7:e1511506. doi:10.1080/2162402X.2018.1511506.

73. Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol. 2011;8:551–561. doi:10.1038/nrclinonc.2011.72.

74. Pierini S, Perales-Linares R, Uribe-Herranz M, Pol JG, Zitvogel L, Kroemer G, Facciabene A, Galluzzi L. Trial watch: DNA-based vaccines for oncological indications. Oncoimmunology. 2017;6:e1398878. doi:10.1080/2162402X.2017.1398878.

75. Hoffman ES, Smith RE, Renaud RC Jr. From the analyst's couch: TLR-targeted therapeutics. Nat Rev Drug Discov. 2005;4:879–880. doi:10.1038/nrd1880.

76. Tyrying S. Imiquimod applied topically: A novel immune response modifier. Skin Therapy Lett. 2001;6:1–4.

77. Dietzch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, Hershberg RM. Coordinated activation of toll-like receptor8 (TLR8) and NLRP3 by the TLR8 agonist, VTX-2337, ignites tumoricidal natural killer cell activity. PloS One. 2016;11:e0148764. doi:10.1371/journal.pone.0148764.

78. Killock D. Haematological cancer: resiquimod-a topical CTCL therapy. Nat Rev Clin Oncol. 2015;12:563. doi:10.1038/nrclinonc.2015.142.

79. Prins RM, Craft N, Bruhn KW, Khan-Farooqui H, Koya RC, Stripecek R, Miller JF, Liau LM. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006;176:157–164. doi:10.4049/jimmunol.176.1.157.

80. Bialojan A, Sohl J, Rausch J, Aranda Lopez P, Denny M, Langguth P, Hartmann A-K, Yagita H, Probst HC, Schild H, et al. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice. Eur J Immunol. 2019;49:2083–2094. doi:10.1002/eji.201840309.

81. Hanter JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS, Birmachu W. Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol. 2008;9:39. doi:10.1186/1471-2172-9-39.

82. Weigel BJ, Cooley S, DeFor T, Weisdorf DJ, Panoskistals-Mortari A, Chen W, Blazar BR, Miller JS. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. Am J Hematol. 2012;87:953–956. doi:10.1002/ajh.23280.
129. Diab A, Marcondes M, Tagliaferrri MA, Hoch U, Zhang J, Rubas W, Kvimae S, Zalevsky J, Conley AP, Borazanci E, et al. REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies. Ann Oncol. 2018;29:viii16–viii147. doi:10.1093/annonc/mdy279.433.

130. Sharma M, Khong H, Få’k F, Bentebibel S-E, Janssen LME, Chesson BC, Creasy CA, Forget M-A, Kahn LMS, Pazdрак B, et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020;11:661. doi:10.1038/s41467-020-14471-1.

131. Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD, Kerwin WS, Casalini JR, Thirstrup DJ, You S, et al. A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor. Sci Transl Med. 2015;7:284ra258. doi:10.1126/scitranslmed.aaa7489.

132. Frazier JP, Bertout JA, Kerwin WS, Moreno-Gonzalez A, Casalini JR, Grenley MO, Beirne E, Watts KL, Keener A, Thirstrup DJ, et al. Multidrug analyses in patients distinguish efficacious cancer agents based on both tumor cell killing and immunomodulation. Cancer Res. 2017;77:2869–2880. doi:10.1158/0008-5472.CAN-17-0084.

133. Dey J, Kerwin WS, Grenley MO, Casalini JR, Trefyak I, Ditzler SH, Thirstrup DJ, Frazier JP, Pierce DW, Carleton M, et al. A platform for rapid, quantitative assessment of multiple drug combinations simultaneously in solid tumors in vivo. PloS One. 2016;11: e0158617. doi:10.1371/journal.pone.0158617.

134. Moreno-Gonzalez A, Olson JM, Klinghoffer RA. Predicting responses to chemotherapy in the context that matters - the patient. Mol Cell Oncol. 2016;3:e1057315. doi:10.1080/23723556.2015.1057315.

135. Syed YY. Anlotinib: first global approval. Drugs. 2018;78:1057–1062. doi:10.1007/s40265-018-0939-x.

136. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA oncol. 2018;4:1569–1575. doi:10.1001/jamaoncol.2018.3039.

137. Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, Lu Y, Shi Y, Wang Z, Jiang L, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118:654–661. doi:10.1038/bjc.2017.478.

138. Kobold S, Wiedemann G, Rothenfusser S, Endres S. Modes of action of TLR7 agonists in cancer therapy. Immunotherapy. 2014;6:1085–1095. doi:10.2217/imt.14.75.

139. Sautes-Fridman C, Cheri-Ficini J, Damotte D, Fisson S, Fridman WH, Cremer I, Dieu-Nosjean M-C. Tumor microenvironment is multifaceted. Cancer Metastasis Rev. 2011;30:13–25. doi:10.1007/s10555-011-9279-y.

140. Leclerc M, Mezquita L, Guillebot De Nerville G, Tilh Y, Malenica I, Chouaib S, Mami-Chouaib F. Recent advances in lung cancer immunotherapy: input of T-CELL epitopes associated with impaired peptide processing. Front Immunol. 2019;10:1505. doi:10.3389/fimmu.2019.01505.

141. Gravett AM, Trautwein N, Stevanovic S, Dalgleish AG, Copier J. Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells. Oncoimmunology. 2018;7:e1438107. doi:10.1080/2162402X.2018.1438107.

142. Farhad M, Rolig AS, Redmond WL. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology. 2018;7:e1434467. doi:10.1080/2162402X.2018.1434467.

143. O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T-cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151–167. doi:10.1038/s41571-018-0142-8.

144. Martinek J, Wu TC, Cadena D, Banchereau J, Palucka K. Interplay between dendritic cells and cancer cells. Int Rev Cell Mol Biol. 2019;348:179–215. doi:10.1016/bs ircmb.2019.07.008.

145. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10:127–140. doi:10.1038/nrd3264.

146. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol. 2006;6:196–204. doi:10.1038/nri1787.